Weekly reads: Trump’s Granddaughter gets MUSE cell injection, fibroblast plasticity, unusual FDA warning

by rss feed | Oct 24, 2026 | Dr. Jeffrey Wiegers, MuseCell Innovations, News Feeds, Trump stem cells, weekly reads

I just wrote about the complicated MUSE cell situation in the US. Marketing of these unapproved cells is all over the place now. It’s so widespread that celebrities and other well-known folks are trying MUSE cells. Trump’s granddaughter’s MUSE cell...

Weekly reads: G&D trio, Regenative Labs sues FDA, OCT4 sub, SpudCells, SRSF1 as an anti-aging factor?

by rss feed | Oct 18, 2026 | News Feeds, Regenative Labs, SpudCells, weekly reads, xenobots

Early on in my career as a graduate student in Mark Kamps’ lab, we had some go-to journals like G&D and MCB. Such journals often published papers in our areas of interest on Hox, Meis, and Pbx proteins as well as pre-B cell ALL. We published there too. For...

Weekly reads: stem cell and peptides via RFK Jr., Urnov vs. Tie exchange fire, med centers cash in on longevity, the end for Caribou

by rss feed | Oct 11, 2026 | Hyagen Medical, News Feeds, weekly reads

What’s the stem cell and peptides connection? The first time I heard of “peptides” (meaning the unproven wellness ones) it was from a fan of unproven stem cell clinics. It was an aha moment of connection. More recently, dubious peptides and stem...

Weekly reads: $100B NIH budget dream, Sholto David on YouTube, Jun Takahashi award, Muse cell developments

by rss feed | Sep 27, 2026 | Muse cell patent, MUSE cells, News Feeds, Sholto David, weekly reads

What should the NIH budget be these days? Certainly higher than it is, but what would the ideal level be? One of my weekly reads is a proposal for $100B in NIH  funding. All things considered, that seems reasonable to me. NIH is a massive engine of innovation for our...

Weekly reads: Longeveron MSC trial disappoints, CRISPR ancestor VIPR, distinct human brain progenitors, FDA staffing woes

by rss feed | Sep 20, 2026 | Longeveron, News Feeds, weekly reads, XPRIZE Healthspan

Longeveron is a biotech focused on mesenchymal stromal/stem cells or MSCs. Its big news this year was a report in Cell Stem Cell about a potential benefit for frailty from its product laromestrocel. I’ll talk more about that and my concerns further down. Now...

Weekly reads: suite of reprogramming news, cancer trial reform, zombie retracted papers

by rss feed | Sep 13, 2026 | IPS cells, News Feeds, Reprogramming, weekly reads

Do you buy the idea of using in vivo reprogramming to fight aging? How about to treat certain diseases? The stream of research pubs and news articles continues to grow. Before we jump into weekly reads including on reprogramming applications, on the 20th anniversary...